CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 176 enrolled
Drug / intervention
highly purified human chorionic gonadotropin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02449889
NCT02449889Phase 3Completed

A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy and Safety of Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation

Ferring Pharmaceuticals·interventional·Posted May 20, 2015·Updated Jun 26, 2019

In Brief

A Phase 3 clinical trial evaluating highly purified human chorionic gonadotropin and recombinant human chorionic gonadotropin for Infertility. Completed, enrolled 176 participants across 1 site.

Detailed Summary

This trial is investigating the efficacy and safety of highly purified human chorionic gonadotropin (HP-hCG) and recombinant human chorionic gonadotropin (rhCG) for triggering of final follicular maturation in women undergoing controlled ovarian stimulation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 20, 2015
Enrollment StartApr 1, 2016
Primary CompletionJul 9, 2017
Study CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.1 years ago

Interventions

highly purified human chorionic gonadotropindrug

recombinant human chorionic gonadotropindrug